• Explore /
  • Poster
  • / A phase 2 trial of darolutamide maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with AR targeting agents and non-progressive on a subsequent taxane (SAKK 08/16).

A phase 2 trial of darolutamide maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with AR targeting agents and non-progressive on a subsequent taxane (SAKK 08/16).

Abstract Poster

Authors

null

Richard Cathomas

Kantonsspital, Chur, Switzerland

Richard Cathomas , Stefanie Hayoz , Andrea Corinne Fuhrer , Christine Biaggi Rudolf , Augusto Pedrazzini , Giuseppe Procopio , Silke Gillessen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02933801

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS5087)

DOI

10.1200/JCO.2018.36.15_suppl.TPS5087

Abstract #

TPS5087

Poster Bd #

313b

Abstract Disclosures

Similar Posters

First Author: Dana E. Rathkopf

First Author: Howard I. Scher

First Author: Benedito A. Carneiro

First Author: Karim Fizazi